The use of lytic viruses to preferentially infect and eliminate cancer cells while sparing
normal cells is a promising experimental therapeutic approach for treating cancer. However …

The high efficacy of therapeutic cancer vaccines in preclinical studies has yet to be fully
achieved in clinical trials. Tumor immune suppression is a critical factor that hampers the …

Our study investigated the immunomodulatory effects of sunitinib to rationally design
combinational platforms with immunotherapies for the treatment of solid tumors. Using a …

Tumor cells harbor tens to thousands of genetic and epigenetic alterations that disrupt
cellular pathways, providing them with growth and survival advantages. However, these …

Oncolytic viruses pose many questions in their use in cancer therapy. In this study, we
assessed the potential of mpJX-594 (mouse-prototype JX-594), a replication-competent …

Despite having potent oncolytic activity, in vitro, direct intratumoral injection of oncolytic
vesicular stomatitis virus (VSV) into established AE17ova mesothelioma tumors in C57Bl/6 …

Oncolytic viruses consist of a diverse range of DNA and RNA viruses traditionally thought to
mediate their effects by exploiting aberrations in tumor pathways, allowing preferential viral …

Oncolytic viruses (OVs) are promising anticancer agents but like other cancer
monotherapies, the genetic heterogeneity of human malignancies can lead to treatment …

Cancer is a traitorous archenemy that threatens our survival. Its ability to evade detection
and adapt to various cancer therapies means that it is a moving target that becomes …

Sunitinib, a protein tyrosine kinase inhibitor is the frontline therapy for renal and
gastrointestinal cancers. We hypothesized that by virtue of its well documented tumor …